Analysts Issue Forecasts for Immunocore FY2025 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Immunocore in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings per share of ($2.33) for the year. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

Several other research analysts also recently weighed in on IMCR. Morgan Stanley restated an “equal weight” rating and set a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. UBS Group started coverage on shares of Immunocore in a research report on Thursday, October 24th. They issued a “sell” rating and a $24.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Thursday, October 24th. Finally, Guggenheim downgraded Immunocore from a “buy” rating to a “neutral” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Stock Up 3.4 %

Shares of NASDAQ:IMCR opened at $30.00 on Wednesday. Immunocore has a twelve month low of $27.69 and a twelve month high of $76.98. The stock’s 50 day moving average is $30.56 and its 200-day moving average is $33.45. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. During the same period in the previous year, the company posted ($0.59) EPS. The firm’s revenue was up 23.7% compared to the same quarter last year.

Hedge Funds Weigh In On Immunocore

Several institutional investors have recently added to or reduced their stakes in IMCR. Exchange Traded Concepts LLC lifted its position in shares of Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after buying an additional 1,461 shares during the last quarter. Connective Portfolio Management LLC purchased a new stake in Immunocore during the third quarter valued at about $218,000. China Universal Asset Management Co. Ltd. boosted its position in Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares during the period. XTX Topco Ltd purchased a new position in shares of Immunocore in the second quarter worth about $303,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Immunocore in the third quarter valued at approximately $406,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.